2024
Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502.
Gandhi S, Ballman K, Holmes M, Visvanathan K, Symington B, Carvan M, Matyka C, Weiss A, Winer E, Razaq W, Carey L, Partridge A, Chen W. Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502. Journal Of Clinical Oncology 2024, 42: 11016-11016. DOI: 10.1200/jco.2024.42.16_suppl.11016.Peer-Reviewed Original ResearchInvasive disease-free survivalBrief Pain InventoryPerceived Stress ScaleOverall survivalPittsburgh Sleep Quality IndexMultivariate Cox modelClinical outcomesBreast cancerCESD-RClinical trialsAssociated with worse clinical outcomesDouble-blind clinical trialCox modelBrief Pain Inventory scoresHormone receptor statusDisease-free survivalEpidemiologic Studies Depression Scale-RevisedCenter for Epidemiologic Studies Depression Scale-RevisedHigher Perceived Stress ScaleBody mass indexNonmetastatic breast cancerSleep qualityCESD-R scoresPerceived Stress Scale scoresPittsburgh Sleep Quality Index score
2022
Survival in male breast cancer over the past 3 decades
Leone J, Freedman R, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N, Hassett M. Survival in male breast cancer over the past 3 decades. Journal Of The National Cancer Institute 2022, 115: 421-428. PMID: 36583555, PMCID: PMC10086618, DOI: 10.1093/jnci/djac241.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalMale breast cancerOverall survivalBreast cancerMultivariable Cox regressionCancer-specific survivalEnd Results registryYear of diagnosisBreast cancer mortalityStage of diseaseLog-rank testCox regressionCancer mortalityKaplan-MeierIndependent associationCox modelSignificant improvementSignificant associationCancerLife expectancyDiagnosisSurvivalSignificant differencesPatientsMen
2021
Survival in male breast cancer (MaBC) over the past three decades.
Leone J, Freedman R, Leone J, Hassett M, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Survival in male breast cancer (MaBC) over the past three decades. Journal Of Clinical Oncology 2021, 39: 569-569. DOI: 10.1200/jco.2021.39.15_suppl.569.Peer-Reviewed Original ResearchBreast cancer-specific survivalOverall survivalBreast cancerCox modelWorse breast cancer-specific survivalHormone receptor-negative statusGrade 3 diseaseCancer-specific survivalEnd Results registryReceptor-negative statusYear of diagnosisMale breast cancerMultivariate Cox modelDecade of diagnosisPeriod of diagnosisBreast cancer mortalityProportional hazards regressionLog-rank testCause of deathPatient characteristicsMedian ageHazards regressionCancer mortalityKaplan-MeierBlack race
2017
Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Martin M, Loibl S, Hyslop T, de la Haba-Rodriguez J, Aktas B, Cirrincione C, Carrasco E, Mehta K, Barry W, Morales S, Carey L, Garcia Saenz J, Partridge A, Martinez N, Hahn O, Winer E, Guerrero A, Hudis C, Casas M, Dickler M. Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Journal Of Clinical Oncology 2017, 35: 1012-1012. DOI: 10.1200/jco.2017.35.15_suppl.1012.Peer-Reviewed Original ResearchProgression-free survivalAdvanced breast cancerRandomized trialsMedian progression-free survivalNegative advanced breast cancerBreast Cancer Research FoundationAddition of BevMultivariable Cox modelAddition of bevacizumabFirst-line treatmentCancer Research FoundationCardiovascular eventsPgR statusSecondary endpointsLiver eventsRecurrent diseaseMedian ageMultivariable analysisTreatment armsPatient populationBreast cancerGrade 3Prolonged benefitCox modelStudy-level differences
2016
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Di Leo A, Malorni L. TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research 2016, 22: 5755-5764. PMID: 27185372, PMCID: PMC5124409, DOI: 10.1158/1078-0432.ccr-16-0148.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalBreast NeoplasmsDisease-Free SurvivalDouble-Blind MethodEpidermal Growth FactorEstradiolFemaleFulvestrantGene Expression ProfilingHepatocyte Nuclear Factor 3-alphaHumansMiddle AgedPostmenopauseReceptors, EstrogenSignal TransductionTranscription Factor AP-2TranscriptomeConceptsProgression-free survivalBreast cancerPredictive biomarkersCONFIRM studyMetastatic estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerGene signatureBiologic pathwaysAdvanced breast cancerMetastatic breast cancerMultivariate Cox modelPotential new therapeutic targetEstrogen receptor antagonistNew therapeutic targetsNegative predictive valuePrimary tumor samplesNovel gene signatureMetastatic ERPrimary ERReceptor antagonistFulvestrant treatmentDecreased responseCox modelER levels
2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal Of Clinical Oncology 2015, 33: 2772-2779. PMID: 26215945, PMCID: PMC4550691, DOI: 10.1200/jco.2015.60.8133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansKi-67 AntigenLetrozoleMiddle AgedNitrilesReceptor, ErbB-2TamoxifenTreatment OutcomeTriazolesConceptsInvasive ductal carcinomaInvasive lobular carcinomaDisease-free survivalLobular carcinomaDFS eventsDuctal carcinomaLA subtypeBreast International Group (BIG) 1Early-stage invasive ductal carcinomaClassic invasive lobular carcinomaHER2-negative invasive ductal carcinomaKi-67 labeling indexLow proliferative activityMagnitude of benefitAdjuvant letrozoleMedian followBIG 1ILC subsetsMultivariable modelCox modelGroup 1LetrozoleCarcinomaLabeling indexPatients
2014
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal Of Cancer 2014, 111: 1532-1541. PMID: 25101563, PMCID: PMC4200088, DOI: 10.1038/bjc.2014.444.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerChemotherapy responseClinical trialsProliferation signatureBreast cancerMultivariable logistic regression modelFuture clinical trialsBasal-like diseaseBasal-like subtypeIntrinsic molecular subtypesClinical pathological dataLogistic regression modelsBLBC subtypeIntrinsic subtypesSignificant interaction testMolecular subtypesCox modelIndependent cohortTNBC heterogeneityClinical implicationsSignificant associationBLBCChemotherapyPhenotypic subtypesLow expression